Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL374670 | 0.81 | HSD17B1 (0.48) | SMN1; SMN2USP2CYP3A4MAPK1CYP1A1 | |
| SCHEMBL3976468 | 0.78 | CYP1A1 (0.44) | SMN1; SMN2MAPK1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL15127717 | 0.73 | NPC1 (0.38) | USP2CYP3A4CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL3970186 | 0.72 | ALDH1A1 (0.40) | CYP3A4CYP1A1CYP1A2CYP1B1KMT2A | |
| SCHEMBL15883267 | 0.71 | ALDH1A1 (0.53) | SMN1; SMN2USP2CYP3A4MAPK1CYP1A1 | |
| SCHEMBL6751046 | 0.71 | KMT2A (0.50) | SMN1; SMN2CYP3A4MAPK1CYP1A2KMT2A | |
| SCHEMBL3970999 | 0.70 | GAA (0.50) | SMN1; SMN2USP2CYP3A4MAPK1CYP1A2 | |
| SCHEMBL6751051 | 0.70 | ALDH1A1 (0.45) | CYP1A1CYP1A2CYP1B1KMT2AMEN1 | |
| SCHEMBL3965223 | 0.68 | KDM4E (0.47) | SMN1; SMN2USP2CYP3A4MAPK1KMT2A | |
| SCHEMBL28333323 | 0.68 | KMT2A (0.53) | SMN1; SMN2MAPK1KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1472231-A1 | 2'-HALO-3',5'-DIALKOXYPHEN-1'-YL-IMINO-2-IMIDAZOLIDINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF URINARY INCONTINENCE | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-6703409-B2 | NITROGEN COMPOUNDS SUCH AS 2'-CHLORO-3',5'-DIMETHOXYPHEN-1'-YL -IMINO-2-IMIDAZOLIDINE OR ISOMERS, USED AS PREFERENTIAL ADRENOCEPTOR AGONISTS FOR PREVENTION OF INCONTINENCE; SIDE EFFECT REDUCTION | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-03-09 | — | — | US | disclosed |
| US-20030162822-A1 | 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-08-28 | — | — | US | disclosed |
| WO-2003064398-A1 | 2'-HALO-3',5'-DIALKOXYPHEN-1'-YL-IMINO-2-IMIDAZOLIDINE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF URINARY INCONTINENCE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | WO | disclosed |
| EP-1333028-A1 | 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162822-A1 | 2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine and the use thereof as a drug | ADRA2C, CLIC1, WNK3 | SMN1; SMN2 2773/4885USP2 2166/4885CYP3A4 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.